Panel Discussion: Evaluating the State-of-Play of AI/ML Applications in Drug Discovery: Is AI Delivering Real ROI in 2026?

• Understanding the state-of-play of AI/ML and computational methods across in silico drug design and complementary integration to improve quality and timelines of drug discovery workflows
• Evaluating applications of AI/ML showing promise through experimental validation and dealmaking versus discovery use cases that remain challenging
• Debating global attitudes and the best approaches to foster global discovery collaborations, highlighting the importance of experimental validation and access to quality data resources

Speakers:

Vanessa Braunstein

Senior Director, TuneLab AI Drug Discovery Platform Ecosystem Growth

Eli Lilly & Co.

Namshik Han

Chief Technology Officer

CardiaTec

Haemin Chon

Vice President & Head, Convergence R&D Center

Hanmi Pharm